The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Open accessAbstract
Recently, in the field of cancer treatment, the paradigm has changed to immunotherapy that activates the immune system to induce cancer attacks. Among them, immune checkpoint inhibitors (ICI) are attracting attention as excellent and continuous clinical results. However, it shows not only limitations such as efficacy only in some patients or some indications, but also side-effects and resistance occur. Therefore, it is necessary to understand the factors of the tumor microenvironment (TME) that affect the efficacy of immunotherapy, that is, the mechanism by which cancer grows while evading or suppressing attacks from the immune system within the TME. Tumors can evade attacks from the immune system through various mechanisms such as restricting antigen recognition, inhibiting the immune system, and inducing T cell exhaustion. In addition, tumors inhibit or evade the immune system by accumulating specific metabolites and signal factors within the TME or limiting the nutrients available to immune cells. In order to overcome the limitations of immunotherapy and develop effective cancer treatments and therapeutic strategies, an approach is needed to understand the functions of cancer and immune cells in an integrated manner based on the TME. In this review, we will examine the effects of the TME on cancer cells and immune cells, especially how cancer cells evade the immune system, and examine anti-cancer strategies based on TME.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
Marofi, F., Al-Awad, A. S., Rahman, H. S., Markov, A. A., Abdelbasset, W. K., Enina, Y. I., Mahmoodi, M., Hassanzadeh, A., Yazdanifar, M., Chartrand, M. S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.673276 · Cited by 101
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Therefore, further research should aim to elucidate the diversity of tumor metabolism in order to develop effective anti-cancer immunotherapy (Hu et al., 2013; Crompton et al., 2015; Hensley et al., 2016; Pavlova and Thompson, 2016; Grzes et al., 2017; Palm et al., 2017; Reid et al., 2017; Badur and au, 2018; Wellenst…”
BackgroundMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · cited 1×
“When the TCR is activated without co-stimulation, excessive activity of calcium/nuclear factor of activated T-cell (NFAT) signals induces the expression of negative modulating factors and T cells become unresponsive (T cell anergy) (Gimmi et al., 1993; Macián et al., 2002; Williams et al., 2006; Chen and Flies, 2013).”
BackgroundThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · cited 1×
“As an alternative to this, cancer cells release ligands to NKG2D, an active receptor of NK cells, to evade lysis by NK cells (Ljunggren and Kärre, 1990; Groh et al., 2002; Terry et al., 2019; Hu et al., 2020).”
BackgroundPrevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Decoding the Patterns of Self and Nonself by the Innate Immune System
Medzhitov, R., & Janeway, C. A. (2002) · Science · doi:10.1126/science.1068883 · Cited by 2,154
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation
Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Tumor-Associated Macrophages in Tumor Immunity
Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583084 · Cited by 1,872
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712 · cited 1×
“It has also been reported that the immune response is suppressed in highdose chemotherapy, while in low-dose chemotherapy, the anticancer immune response is stimulated or induced (Zitvogel et al., 2008; Galluzzi et al., 2015).”
BackgroundInhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Regulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
LeBleu, V. S., O’Connell, J. T., Gonzalez Herrera, K. N., Wikman, H., Pantel, K., Haigis, M. C., de Carvalho, F. M., Damascena, A., Domingos Chinen, L. T., Rocha, R. M., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3039 · Cited by 1,404
Lactate Metabolism in Human Lung Tumors
Faubert, B., Li, K. Y., Cai, L., Hensley, C. T., Kim, J., Zacharias, L. G., Yang, C., Do, Q. N., Doucette, S., Burguete, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.019 · Cited by 1,343
The cancer metabolic reprogramming and immune response
Xia, L., Oyang, L., Lin, J., Tan, S., Han, Y., Wu, N., Yi, P., Tang, L., Pan, Q., Rao, S., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01316-8 · Cited by 1,312
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B.-S., Kroemer, G., & Galluzzi, L. (2018) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,273
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Watson, M. J., Vignali, P. D. A., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N. L., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,259
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Angelin, A., Gil-de-Gómez, L., Dahiya, S., Jiao, J., Guo, L., Levine, M. H., Wang, Z., Quinn, W. J., Kopinski, P. K., Wang, L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.018 · Cited by 1,246
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169 · cited 1×
“, 2005), and glutamine (Cheng et al., 2011; Wang et al., 2011; Leone et al., 2019)), conditions of high acidity and high lactic acid levels, and upregulation of immune checkpoints.”
BackgroundImmunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Metabolic heterogeneity in human lung tumors
Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., Jiang, L., Ko, B., Skelton, R., Loudat, L., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.034 · Cited by 1,138
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
A2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
Sinclair, L. V., Rolf, J., Emslie, E., Shi, Y.-B., Taylor, P. M., & Cantrell, D. A. (2013) · Nature Immunology · doi:10.1038/ni.2556 · Cited by 930
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892
Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells
Kudo-Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.023 · Cited by 870
Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013) · Immunology · doi:10.1111/imm.12036 · Cited by 815
Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 810
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
Williams, M. A., Tyznik, A. J., & Bevan, M. J. (2006) · Nature · doi:10.1038/nature04790 · Cited by 797
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
The transcriptional repressor Snail promotes mammary tumor recurrence
Moody, S. E., Perez, D., Pan, T.-C., Sarkisian, C. J., Portocarrero, C. P., Sterner, C. J., Notorfrancesco, K. L., Cardiff, R. D., & Chodosh, L. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.009 · Cited by 750
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Transcriptional Mechanisms Underlying Lymphocyte Tolerance
Macián, F., Garcı́a-Cózar, F., Im, S.-H., Horton, H. F., Byrne, M. C., & Rao, A. (2002) · Cell · doi:10.1016/s0092-8674(02)00767-5 · Cited by 687
Yang, C., Ko, B., Hensley, C. T., Jiang, L., Wasti, A. T., Kim, J., Sudderth, J., Calvaruso, M. A., Lumata, L., Mitsche, M., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.025 · Cited by 679
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 639
Targeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Tumor-Associated Macrophages: Recent Insights and Therapies
Zhou, J., Tang, Z., Gao, S., Li, C., Feng, Y., & Zhou, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00188 · Cited by 619 · cited 1×
“Tumor-associated macrophages are immune cells that regulate various factors in the tumor microenvironment and play an important role in connecting cancer with various immune cells in the tumor microenvironment (Pan et al., 2020; Zhou et al., 2020).”
BackgroundTang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
Hossain, F., Al-Khami, A. A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0036 · Cited by 588
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.
Gimmi, C. D., Freeman, G. J., Gribben, J. G., Gray, G., & Nadler, L. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6586 · Cited by 548
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer
Qu, Q., Zeng, F., Liu, X., Wang, Q. J., & Deng, F. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.132 · Cited by 545
The impact of cellular metabolism on chromatin dynamics and epigenetics
Reid, M. A., Dai, Z., & Locasale, J. W. (2017) · Nature Cell Biology · doi:10.1038/ncb3629 · Cited by 515
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
Pyruvate carboxylase is required for glutamine-independent growth of tumor cells
Cheng, T., Sudderth, J., Yang, C., Mullen, A. R., Jin, E. S., Matés, J. M., & DeBerardinis, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016627108 · Cited by 475
Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass
Spinelli, J. B., Yoon, H., Ringel, A. E., Jeanfavre, S., Clish, C. B., & Haigis, M. C. (2017) · Science · doi:10.1126/science.aam9305 · Cited by 468
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464 · cited 2×
“Cancer inhibits DC maturation through tumor derived-factors such as IL-10 (Williams et al., 2004), macrophage colony-stimulating factor (MCSF) (Nefedova et al., 2004), vascular endothelial growth factor (VEGF) (Gabrilovich et al., 1996), prostaglandin (Sá-Nunes et al., 2007), TGF-β (Zong et al., 2016), and indoleamine…”
BackgroundStrauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0472 · Cited by 453
Celià-Terrassa, T., Meca-Cortés, Ó., Mateo, F., Martínez de Paz, A., Rubio, N., Arnal-Estapé, A., Ell, B. J., Bermudo, R., Díaz, A., Guerra-Rebollo, M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59218 · Cited by 450
Adenosine receptors in regulation of dendritic cell differentiation and function
Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2008) · Blood · doi:10.1182/blood-2008-02-136325 · Cited by 430 · cited 3×
“In addition, immunosuppressive cells in the TME, such as Treg and myeloid-derived suppressor cells (MDSCs) express inhibitory factors that suppress DC maturation, reducing the expression of MHC and co-stimulatory factors in DCs, resulting in reduced production of inflammatory cytokines, such as IL-12, and ultimately i…”
BackgroundTrafficking of T Cells into Tumors
Slaney, C. Y., Kershaw, M. H., & Darcy, P. K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2458 · Cited by 410
Heterogeneity of tumor-induced gene expression changes in the human metabolic network
Hu, J., Locasale, J. W., Bielas, J. H., O'Sullivan, J., Sheahan, K., Cantley, L. C., Heiden, M. G. V., & Vitkup, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2530 · Cited by 407
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
Campoli, M., & Ferrone, S. (2008) · Oncogene · doi:10.1038/onc.2008.273 · Cited by 404
Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399
Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas
Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3292 · Cited by 395
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.017 · Cited by 387
Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment
Renner, K., Singer, K., Koehl, G. E., Geissler, E. K., Peter, K., Siska, P. J., & Kreutz, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00248 · Cited by 374
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors
Andrejeva, G., & Rathmell, J. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.004 · Cited by 373
Cellular Constituents of Immune Escape within the Tumor Microenvironment
Kerkar, S. P., & Restifo, N. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4094 · Cited by 370
Crompton, J. G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R. L., Tran, E., Hanada, K.-I., Yu, Z., Palmer, D. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2277 · Cited by 345
As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid
Pavlova, N. N., Hui, S., Ghergurovich, J. M., Fan, J., Intlekofer, A. M., White, R. M., Rabinowitz, J. D., Thompson, C. B., & Zhang, J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.12.006 · Cited by 341
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Targeting metabolism to regulate immune responses in autoimmunity and cancer
Patel, C. H., Leone, R. D., Horton, M. R., & Powell, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0032-5 · Cited by 306
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Taylor, B. C., & Balko, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844866 · Cited by 298
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
Mechanism and its regulation of tumor-induced angiogenesis
Gupta, M. K. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1144 · Cited by 294
Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 291
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
Shioiri, M., Shida, T., Koda, K., Oda, K., Seike, K., Nishimura, M., Takano, S., & Miyazaki, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603193 · Cited by 287
CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond
Karin, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00976 · Cited by 278
Schaefer, C., Kim, G. G., Albers, A., Hoermann, K., Myers, E. N., & Whiteside, T. L. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602407 · Cited by 271
Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1263412 · Cited by 253
Interleukin‐10 suppression of myeloid cell activation — a continuing puzzle
Williams, L. M., Ricchetti, G., Sarma, U., Smallie, T., & Foxwell, B. M. J. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01988.x · Cited by 234
B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2
Shi, T., Ma, Y., Cao, L., Zhan, S., Xu, Y., Fu, F., Liu, C., Zhang, G., Wang, Z., Wang, R., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1549-6 · Cited by 228
Tripathi, S. C., Peters, H. L., Taguchi, A., Katayama, H., Wang, H., Momin, A., Jolly, M. K., Celiktas, M., Rodriguez-Canales, J., Liu, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521812113 · Cited by 204
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
Kouidhi, S., Ben Ayed, F., & Benammar Elgaaied, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00353 · Cited by 196
Corbet, C., Bastien, E., Draoui, N., Doix, B., Mignion, L., Jordan, B. F., Marchand, A., Vanherck, J.-C., Chaltin, P., Schakman, O., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03525-0 · Cited by 188
Chen, X., Song, X., Li, K., & Zhang, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00292 · Cited by 174
Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy
Rivera, G. O. R., Knochelmann, H. M., Dwyer, C. J., Smith, A. S., Wyatt, M. M., Rivera-Reyes, A. M., Thaxton, J. E., & Paulos, C. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645242 · Cited by 173
A landscape of metabolic variation across tumor types
Reznik, E., Luna, A., Aksoy, B. A., Liu, E. M., La, K., Ostrovnaya, I., Creighton, C. J., Hakimi, A. A., & Sander, C. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.014 · Cited by 172
When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance
Kuo, C., & Ann, D. K. (2018) · 癌症:英文版 · doi:10.1186/s40880-018-0317-9 · Cited by 170
The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer
Kuo, P. T., Zeng, Z., Salim, N., Mattarollo, S., Wells, J. W., & Leggatt, G. R. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00271 · Cited by 167
Tumor-derived factors modulating dendritic cell function
Zong, J., Keskinov, A. A., Shurin, G. V., & Shurin, M. R. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1820-y · Cited by 164
Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy
Bourgeois, T. L., Strauss, L., Aksoylar, H., Daneshmandi, S., Seth, P., Patsoukis, N., & Boussiotis, V. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00237 · Cited by 162
Immunobiology of head and neck cancer
Whiteside, T. L. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-5050-6 · Cited by 161
CCL2 is critical for immunosuppression to promote cancer metastasis
Kudo‐Saito, C., Shirako, H., Ohike, M., Tsukamoto, N., & Kawakami, Y. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9545-6 · Cited by 157
Yang, F., Takagaki, Y., Yoshitomi, Y., Ikeda, T., Li, J., Kitada, M., Kumagai, A., Kawakita, E., Shi, S., Kanasaki, K., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0620 · Cited by 134
Sá‐Nunes, A., Báfica, A. L. B., Lucas, D. A., Conrads, T. P., Veenstra, T. D., Andersen, J. F., Mather, T. N., Ribeiro, J. M. C., & Francischetti, I. M. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1497 · Cited by 130
Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes
Wang, T., Notta, F., Navab, R., Joseph, J., Ibrahimov, E., Xu, J., Zhu, C.-Q., Borgida, A., Gallinger, S., & Tsao, M.-S. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0192 · Cited by 123
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 121
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Shadbad, M. A., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 120
Sangaletti, S., Tripodo, C., Santangelo, A., Castioni, N., Portararo, P., Gulino, A., Botti, L., Parenza, M., Cappetti, B., Orlandi, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.075 · Cited by 114
Naidoo, J., Page, D. B., & Wolchok, J. D. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.002 · Cited by 108
HWANG, S. L., Chung, N. P. Y., Chan, J. K., & Lin, C.-L. S. (2005) · Cell Research · doi:10.1038/sj.cr.7290282 · Cited by 107
Integration of omics: more than the sum of its parts
Buescher, J., & Driggers, E. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0143-y · Cited by 103
Grandis, J. R., Falkner, D. H., Melhem, M. F., Gooding, W. E., Drenning, S. D., & Morel, P. A. (2000) · PubMed · Cited by 99
Lu, Y., Dong, B., Xu, F., Xu, Y., Pan, J., Song, J., Zhang, J., Huang, Y., & Xue, W. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0434-3 · Cited by 94
Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma
Li, C., Shintani, S., Terakado, N., Nakashiro, K., & Hamakawa, H. (2002) · Oncology Reports · doi:10.3892/or.9.6.1219 · Cited by 93
Lee, E. K., Xiong, N., Cheng, S., Barry, W. T., Penson, R. T., Konstantinopoulos, P. A., Hoffman, M. A., Horowitz, N. S., Dizon, D. S., Stover, E. H., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.028 · Cited by 93
Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
Zhang, M., Jin, X. K., Sun, R., Xiong, X., Wang, J., Xie, D., & Zhao, M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03165-x · Cited by 93
Metabolic reprogramming in tumors: Contributions of the tumor microenvironment
Lane, A. N., Higashi, R. M., & Fan, T. W.-M. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2019.10.007 · Cited by 91
Critical role for PI3-kinase in regulating the use of proteins as an amino acid source
Palm, W., Araki, J., King, B., Dematteo, R. G., & Thompson, C. B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712726114 · Cited by 89
Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12
Chung, B., Esmaeili, A. A., Gopalakrishna-Pillai, S., Murad, J. P., Andersen, E. S., Reddy, N. K., Srinivasan, G., Armstrong, B., Chu, C. T., Kim, Y., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0008-8 · Cited by 88
Fighting in a wasteland: deleterious metabolites and antitumor immunity
Watson, M. J., & Delgoffe, G. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148549 · Cited by 86
EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction
Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., Thiery, J. P., Mami‐Chouaib, F., & Chouaïb, S. (2013) · Autophagy · doi:10.4161/auto.24728 · Cited by 84
AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Terry, S., Abdou, A., Engelsen, A. S. T., Buart, S., Dessen, P., Corgnac, S., Collares, D., Meurice, G., Gausdal, G., Baud, V., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0903 · Cited by 84
Kim, M. J., Sun, H. J., Song, Y. S., Yoo, S., Kim, Y. A., Seo, J., Park, Y. J., & Cho, S. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-49613-z · Cited by 84
Self-citationT-Regulatory Cells In Tumor Progression And Therapy
Verma, A., Mathur, R., Farooque, A., Kaul, V., Gupta, S., & Dwarakanath, B. S. R. (2019) · Cancer Management and Research · doi:10.2147/cmar.s228887 · Cited by 81
Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy
Grzes, K. M., Swamy, M., Hukelmann, J. L., Emslie, E., Sinclair, L. V., & Cantrell, D. A. (2017) · Leukemia · doi:10.1038/leu.2017.160 · Cited by 80
Bouris, P., Manou, D., Sopaki-Valalaki, A., Kolokotroni, A., Moustakas, A., Kapoor, A., Iozzo, R. V., Karamanos, N. K., & Theocharis, A. D. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.05.011 · Cited by 72
Kuss, I., Hathaway, B. M., Ferris, R. L., Gooding, W. E., & Whiteside, T. L. (2004) · KARGER eBooks · doi:10.1159/000082506 · Cited by 66
Lin, Y., Ma, Q., Li, L., & Wang, H. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2017-0074 · Cited by 64
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
Bauman, J. E., & Ferris, R. L. (2013) · Cancer · doi:10.1002/cncr.28380 · Cited by 63
Turning the Tide Against Regulatory T Cells
Han, S., Toker, A., Liu, Z. Q., & Ohashi, P. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00279 · Cited by 60
Yang, Z., Xie, H., He, D., & Li, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9873 · Cited by 59
Matsushita, K., Toiyama, Y., Tanaka, K., Saigusa, S., Hiro, J., Uchida, K., Inoue, Y., & Kusunoki, M. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1993-8 · Cited by 57
Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy
Leone, R. D., & Powell, J. D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0791 · Cited by 55
Ma, J., Sun, X., Wang, Y., Chen, B., Qian, L., & Wang, Y. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0432-5 · Cited by 54
Zarychta, E., & Ruszkowska-Ciastek, B. (2022) · Biomedicines · doi:10.3390/biomedicines10020300 · Cited by 53
Shan, S., Lv, Q., Zhao, Y., Liu, C., Sun, Y., Ke-min, X., Xiao, J., & Li, C. (2015) · PubMed · Cited by 52
The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment
Holubec, L., Polívka, J., Šafanda, M., Karas, M., & Liška, V. (2016) · Anticancer Research · doi:10.21873/anticanres.10985 · Cited by 52
Badur, M. G., & Metallo, C. M. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.11.013 · Cited by 49
Qin, H., Valentino, J., Manna, S., Tripathi, P. K., Bhattacharya-Chatterjee, M., Foon, K. A., O'Malley, B. W., & Chatterjee, S. K. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0493 · Cited by 44
Functional control of regulatory T cells and cancer immunotherapy
Wang, R. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.004 · Cited by 44
The Effect of High Mobility Group Box-1 Protein on Splenic Dendritic Cell Maturation in Rats
Zhu, X.-M., Yao, Y.-M., Liang, H., Xu, S., Dong, N., Yu, Y., & Sheng, Z.-Y. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0104 · Cited by 42
Hu, B., Tian, X., Liu, Y., Liu, Y., Yang, T., An, J., An, J., Kong, L., & Li, Y. (2020) · Cancer Medicine · doi:10.1002/cam4.2871 · Cited by 42
Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance
Traba, J., Sack, M. N., Waldmann, T. A., & Antón, O. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657293 · Cited by 41
Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells
Saijo, A., Goto, H., Nakano, M., Mitsuhashi, A., Aono, Y., Hanibuchi, M., Ogawa, H., Uehara, H., Kondo, K., & Nishioka, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.016 · Cited by 36
Schroeder, C. P., Yang, P., Newman, R. A., & Lotan, R. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.9.1037 · Cited by 33
Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance
Weng, C.-Y., Kao, C.-X., Chang, T., & Huang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031258 · Cited by 33
Immunotherapy in head and neck cancer: current practice and future possibilities
Agada, F. O., Alhamarneh, O., Stafford, N., & Greenman, J. (2008) · The Journal of Laryngology & Otology · doi:10.1017/s0022215108003356 · Cited by 17
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37
“This sequence of events is referred to as the cancer–immune cycle [62].”
Background
Metadata
- Authors
- Kim, S. K., & Cho, S. W.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-05-24
- Volume
- 13
- Pages
- 868695-868695
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4281389645
- Cited by
- 460
- References
- 169
- FWCI
- 34.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.